TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Epinephrine and I.V. Needle on CPR Outcome
Brief Summary: Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: OTHER; Interventions: Other: Manual | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual; Assigned to Arm(s): 2
B: Arm Label: Active Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Quality improvement | Arm Label: Control Hospitals; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Quality improvement; Assigned to Arm(s): Active Intervention
C: Arm Label: Adrenaline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adrenaline | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Adrenaline; Assigned to Arm(s): Adrenaline | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin
D: Arm Label: IV yes; Type: EXPERIMENTAL; Interventions: Drug: Epinephrine, Device: Intravenous needle, Drug: Atropine, Drug: Amiodarone | Arm Label: IV no; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): IV yes | Intervention Type: DEVICE; Name: Intravenous needle; Assigned to Arm(s): IV yes | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): IV yes | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): IV yes

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial
Brief Summary: A growing body of evidence links Chlamydia pneumoniae to the progression of coronary heart disease. The purpose of this study is to determine the positive and negative effect of 14 days treatment with clarithromycin 500 mg daily in patients already suffering from stable coronary heart disease. The participants will be followed for at least two years after the treatment.

Abbott Laboratories supplied Clarithromycin and placebo tablets.


Options:
A: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): Clarithromycin, Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: erythromycin group; Type: N/A; Interventions: N/A | Arm Label: control group; Type: N/A; Interventions: N/A
D: Arm Label: Doxycycline; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: Standard Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Current medical therapy for AMI | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Doxycycline | Intervention Type: DRUG; Name: Current medical therapy for AMI; Assigned to Arm(s): Standard Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial
Brief Summary: A growing body of evidence links Chlamydia pneumoniae to the progression of coronary heart disease. The purpose of this study is to determine the positive and negative effect of 14 days treatment with clarithromycin 500 mg daily in patients already suffering from stable coronary heart disease. The participants will be followed for at least two years after the treatment.

Abbott Laboratories supplied Clarithromycin and placebo tablets.


Options:
A: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Drug: VCD induction therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: VCD induction therapy | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VCD induction therapy; Assigned to Arm(s): Clarithromycin, Placebo
B: Intervention Type: DRUG; Name: Intravenous Clarithromycin; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): azithromycin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): Clarithromycin, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects
Brief Summary: The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension. Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004. Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.


Options:
A: Arm Label: Secukinumab 300 mg every 2 weeks (Q2W); Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg | Arm Label: Secukinumab 300 mg every 4 weeks (Q4W); Type: ACTIVE_COMPARATOR; Interventions: Drug: secukinumab 150 mg | Arm Label: Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up); Type: ACTIVE_COMPARATOR; Interventions: Drug: secukinumab 150 mg | Intervention Type: DRUG; Name: secukinumab 150 mg; Assigned to Arm(s): Secukinumab 300 mg every 2 weeks (Q2W), Secukinumab 300 mg every 4 weeks (Q4W), Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)
B: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
C: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
D: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects
Brief Summary: The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension. Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004. Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.


Options:
A: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control
D: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects
Brief Summary: The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension. Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004. Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg
B: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
D: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects
Brief Summary: The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension. Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004. Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.


Options:
A: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
C: Arm Label: CNTO 1959 (5 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (5 mg) | Arm Label: CNTO 1959 (15 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (15 mg) | Arm Label: CNTO 1959 (50 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (50 mg) | Arm Label: CNTO 1959 (100 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (100 mg) | Arm Label: CNTO 1959 (200 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (200 mg) | Arm Label: Adalimumab (approved psoriasis dosing); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: Placebo to CNTO 1959 (100 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1959 (100 mg), Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1959 (5 mg); Assigned to Arm(s): CNTO 1959 (5 mg) | Intervention Type: DRUG; Name: CNTO 1959 (15 mg); Assigned to Arm(s): CNTO 1959 (15 mg) | Intervention Type: DRUG; Name: CNTO 1959 (50 mg); Assigned to Arm(s): CNTO 1959 (50 mg) | Intervention Type: DRUG; Name: CNTO 1959 (100 mg); Assigned to Arm(s): CNTO 1959 (100 mg), Placebo to CNTO 1959 (100 mg) | Intervention Type: DRUG; Name: CNTO 1959 (200 mg); Assigned to Arm(s): CNTO 1959 (200 mg) | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab (approved psoriasis dosing) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to CNTO 1959 (100 mg)
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Guided Care: Integrating High Tech and High Touch
Brief Summary: The purpose of the study is to evaluate the effect of a Guided Care nurse on the quality of the health and well-being of the frail elderly. A specially trained registered nurse will work closely with 1-3 primary care physicians to provide the most complex older patients (and their unpaid caregivers) with health care that is comprehensive, coordinated, patient-centered, and proactive. The study will evaluate the effects of Guided Care on:

* older persons' physical and mental health, health services utilization, quality of care, self-efficacy, and satisfaction with care;
* older persons' unpaid caregivers' burden; and
* primary care physicians' satisfaction with their care of chronically ill patients.


Options:
A: Arm Label: PREPARE; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE website | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Advance directive | Intervention Type: BEHAVIORAL; Name: PREPARE website; Assigned to Arm(s): PREPARE | Intervention Type: BEHAVIORAL; Name: Advance directive; Assigned to Arm(s): CONTROL
B: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
C: Arm Label: Guided Care; Type: EXPERIMENTAL; Interventions: Behavioral: Guided Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Guided Care; Assigned to Arm(s): Guided Care
D: Arm Label: G_AH; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care group | Arm Label: G_SP; Type: OTHER; Interventions: Other: Phone-based care group | Arm Label: G_NOMHAD; Type: EXPERIMENTAL; Interventions: Device: Platform NOMHADchronic | Intervention Type: DEVICE; Name: Platform NOMHADchronic; Assigned to Arm(s): G_NOMHAD | Intervention Type: OTHER; Name: Phone-based care group; Assigned to Arm(s): G_SP | Intervention Type: OTHER; Name: Usual care group; Assigned to Arm(s): G_AH

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telemedicine and Anger Management Groups for PTSD Veterans in the Hawaiian Islands
Brief Summary: Telemedicine has the potential to profoundly influence the delivery of specialized care to the remote veteran population suffering with PTSD. Preliminary research supports telemedicine technology as a possible solution to improve access to mental health services for veterans with PTSD. The proposed research is a treatment-outcome study that will assess the clinical efficacy of conducting an Anger Management Therapy (AMT) group treatment intervention using a videoteleconferencing (VTC) modality as compared to the traditional in-person modality with veterans who have PTSD and reside in remote locations on the Hawaiian Islands. AMT is a manual-guided cognitive-behavioral, skill based group intervention that has been used nationwide in VA substance abuse programs and most recently has been adopted by many VA PTSD Clinical Teams to treat anger-related to the sequelae of PTSD.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Transtelephonic monitoring (TTM) | Arm Label: Remote; Type: ACTIVE_COMPARATOR; Interventions: Other: Medtronic CareLink® Network | Intervention Type: OTHER; Name: Transtelephonic monitoring (TTM); Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Medtronic CareLink® Network; Assigned to Arm(s): Remote
B: Arm Label: Videoteleconferencing AMT; Type: EXPERIMENTAL; Interventions: Behavioral: 12 sessions Anger Management Therapy. | Arm Label: Face to Face AMT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 12 sessions Anger Management Therapy. | Intervention Type: BEHAVIORAL; Name: 12 sessions Anger Management Therapy.; Assigned to Arm(s): Face to Face AMT, Videoteleconferencing AMT
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention - a validated home BP monitor and support from the specialist nurse | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control - usual care (BP monitoring by their practice) | Intervention Type: BEHAVIORAL; Name: Intervention - a validated home BP monitor and support from the specialist nurse; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Control - usual care (BP monitoring by their practice); Assigned to Arm(s): Control
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Two way audio/video telemedicine consult | Intervention Type: OTHER; Name: Telephone; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Two way audio/video telemedicine consult; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Individual-based Diet and Physical Activity Intervention Program to Prevent Accumulation of Abdominal Fat Mass in Recently Retired Men and Women
Brief Summary: Advancing age in itself is associated with changes in body composition. However, during transitional life stages, such as retirement, detrimental changes on diet and physical activity may occur. This might lead to weight gain and accumulation of abdominal fat.

To prevent these changes, participants receive a low-intensity intervention on energy balance and related behaviours.

After six months, one and two years, the effects will be studied by comparing the intervention group with the control group.


Options:
A: Arm Label: Face-to-face counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face counseling | Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counseling | Arm Label: Mail contact; Type: ACTIVE_COMPARATOR; Interventions: Other: Mail contact | Intervention Type: BEHAVIORAL; Name: Face-to-face counseling; Assigned to Arm(s): Face-to-face counseling | Intervention Type: BEHAVIORAL; Name: Telephone counseling; Assigned to Arm(s): Telephone Counseling | Intervention Type: OTHER; Name: Mail contact; Assigned to Arm(s): Mail contact
B: Intervention Type: BEHAVIORAL; Name: Behavior change on physical activity and diet; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: preventative dietary intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Internet weight loss with SlimFast and human counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet weight loss with SlimFast and computer counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet weight loss program with SlimFast; Assigned to Arm(s): N/A

Answer: B